1:24 PM
 | 
Oct 05, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

Omeros Corp. (NASDAQ:OMER) reported data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for 12 weeks led to a 0.4% greater reduction in median proteinuria vs. placebo (18.4% vs. 18%).

The Phase II trial enrolled a cohort of 12 IgA nephropathy patients at high risk of progression who did not receive corticosteroid treatment for the three months prior to screening or during the study, and...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >